A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2003-12-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.290.21.2805PMID 14657064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study.

  2005cited by this paper
• Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

  2003cited by this paper
• Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.

  2003cited by this paper
• Are β-blockers efficacious as first-line therapy for hypertension in the elderly?

  2003cited by this paper
• A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.

  2003cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality.

  2003cited by this paper
• Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• THE EFFECT OF IRBESARTAN ON THE DEVELOPMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood Pressure lowering Drugs

  2001cited by this paper
• THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION

  2000cited by this paper
• Efficacy and Safety of a New Long-acting Drug Combination, Trandolapril/Verapamil as Compared to Monotherapy in Primary Hypertension

  2000cited by this paper
• Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.

  2000cited by this paper
• Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

  2000cited by this paper
• Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.

  2000cited by this paper
• Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

  2000cited by this paper
• Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

  2000cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study.

  1999cited by this paper
• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

  1998cited by this paper
• Verapamil use in patients with cardiovascular disease: An overview of randomized trials

  1998cited by this paper
• Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

  1998cited by this paper
• Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review

  1998cited by this paper
• The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk.

  1997cited by this paper
• Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding

  1997cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials.

  1996cited by this paper
• The risk of myocardial infarction associated with antihypertensive drug therapies.

  1995cited by this paper
• The role of calcium antagonists in ischaemic heart disease.

  1995cited by this paper
• Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

  1995cited by this paper
• Insurance against injury in clinical trials

  1994cited by this paper
• The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

  1993cited by this paper
• Diabetes incidence in users and non‐users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12‐year prospective population study of women in Gothenburg, Sweden

  1992cited by this paper
• Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.

  1992cited by this paper
• Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

  1991cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy.

  2025cites this paper
• Advancements in Beta-Adrenergic Therapy and Novel Personalised Approach for Portal Hypertension: A Narrative Review

  2025cites this paper
• Hypertension precision medicine: the promise and pitfalls of pharmacogenomics.

  2025cites this paper
• Comparative efficacy of different antihypertensive drug classes for stroke prevention: A network meta-analysis of randomized controlled trials

  2025cites this paper
• Efficacy and safety of intensive antihypertensive strategy in patients with low diastolic blood pressure: a secondary analysis of a cluster randomised trial

  2025cites this paper
• A lightweight graph neural network to predict long-term mortality in coronary artery disease patients: an interpretable causality-aware approach

  2025cites this paper
• Hypertension in atherosclerotic cardiovascular disease: insights into epidemiology, management strategies, and outcomes

  2025cites this paper
• Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.

  2025cites this paper
• Data-driven cluster analysis and external validation identify phenotypic subgroups in renin-independent aldosteronism with differential cardiovascular risk and therapeutic implications

  2025cites this paper
• Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.

  2025cites this paper
• Blood pressure management in secondary prevention after myocardial infarction

  2025cites this paper
• Intensive Versus Standard Blood Pressure Control in Type 2 Diabetes: Cardiovascular and Microvascular Outcomes.

  2025cites this paper
• Hypertension in metabolic syndrome

  2025cites this paper
• Maximizing blood pressure lowering effects: a review of drug class comparisons and rationale for combination approaches

  2025cites this paper
• Examining the therapeutic potential and side effects of calcium channel blockers in mortality and morbidity of patients with stroke: A systematic review of pre-clinical and clinical studies

  2025cites this paper
• Triglyceride-glucose index predicts adverse cardiovascular events in patients with H-type hypertension combined with coronary heart disease: a retrospective cohort study

  2025cites this paper
• Multiple triglyceride-derived metabolic indices and incident cardiovascular outcomes in patients with type 2 diabetes and coronary heart disease

  2024cites this paper
• A beta blocker and ACE inhibitor combination in treating hypertension and its complications

  2024cites this paper
• The Digital Platform and Its Emerging Role in Decentralized Clinical Trials

  2024cites this paper
• Intensive blood pressure control in isolated systolic hypertension: a post hoc analysis of a cluster randomized trial

  2024cites this paper
• In remembrance: the life and legacy of George L. Bakris (1952-2024).

  2024cites this paper
• Agreement Between Mega-Trials and Smaller Trials

  2024cites this paper
• Agreement between mega-trials and smaller trials: a meta-research study

  2024cites this paper
• In-hospital systolic blood pressure lowering patterns and risk of rehospitalization for angina in patients with hypertension and coronary artery disease

  2024cites this paper
• The association of coronary artery disease with heart rate at anaerobic threshold and respiratory compensatory point

  2024cites this paper
• In remembrance: the life and legacy of George L. Bakris (1952–2024)

  2024cites this paper
• Efficacy of beta-blockers on blood pressure control and morbidity and mortality endpoints in hypertensives of African ancestry: an individual patient data meta-analysis

  2024cites this paper
• Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo

  2024cites this paper
• Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines

  2024cites this paper
• Triglyceride-glucose index as a potential predictor of major adverse cardiovascular and cerebrovascular events in patients with coronary heart disease complicated with depression

  2024cites this paper
• Ancestry, ethnicity, and race: explaining inequalities in cardiometabolic disease.

  2024cites this paper
• Association between the triglyceride-glucose index and 1-year major adverse cardiovascular events in patients with coronary heart disease and hypertension

  2023cites this paper
• Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI2D Trial.

  2023cites this paper
• Decoding the Interplay of Genes and MicroRNAs in Cardiovascular Disease

  2023cites this paper
• 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

  2023cites this paper
• (Why to use fixed dose perindopril, bisoprolol combination in hypertonics with CHD?)

  2023cites this paper
• Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions

  2023cites this paper
• Triglyceride–glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension

  2023cites this paper
• Beta-Blockers and Hypertension: Some Questions and Answers

  2023cites this paper
• Impact of Preprocedural Diastolic Blood Pressure on Outcomes in Patients Undergoing Percutaneous Coronary Intervention

  2023cites this paper
• Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension

  2023cites this paper
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

  2023cites this paper
• 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.

  2023cites this paper
• Assessment of adherence to therapy in comorbid patients

  2023cites this paper
• 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

  2023cites this paper
• Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial

  2022cites this paper
• Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials.

  2022cites this paper
• Hypertension management in patients with cardiovascular comorbidities.

  2022cites this paper
• Angina in 2022: Current Perspectives

  2022cites this paper
• Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

  2022cites this paper
• Are U‐shaped relationships between risk factors and outcomes artifactual?

  2022cites this paper
• Self-Assessment of Outpatient Management of Hypertension in Diabetics

  2022cites this paper
• Optimizing therapy for cardiovascular diseases: proven organ-protective and preventive effects of pitavastatin and lercanidipine: A review

  2022cites this paper
• 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

  2022cites this paper
• Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines.

  2022cites this paper
• Controversies in Hypertension II: the Optimal Target Blood Pressure.

  2022cites this paper
• Calcium channel blockers versus other classes of drugs for hypertension.

  2022cites this paper
• Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

  2022cites this paper
• Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?

  2022cites this paper
• Sex differences in hypertension. Do we need a sex-specific guideline?

  2022cites this paper
• Blood Pressure and Risk of Cardiovascular Disease in UK Biobank: A Mendelian Randomization Study.

  2021cites this paper
• A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data

  2021cites this paper
• Guide de Pratique Clinique. Prise en charge de l’hypertension artérielle chez l’adulte en Tunisie

  2021influential citation
• A systematic review of methods used to conduct decentralised clinical trials

  2021cites this paper
• Determination of Patient Characteristics and Role of Physician Intervention for Uncontrolled Hypertension: A Risk for Coronary Artery Disease

  2021cites this paper
• The Importance of Use of Genetics to Guide Hypertension Therapy

  2021cites this paper
• Calcium channel blockers versus other classes of drugs for hypertension.

  2021cites this paper
• The diastolic blood pressure J-curve revisited: An update

  2021cites this paper
• The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases

  2021cites this paper
• Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

  2021cites this paper
• Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome‐Wide Interaction Meta‐Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies

  2021cites this paper
• A pathophysiological compass to personalize antianginal drug treatment

  2021cites this paper
• Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom.

  2021cites this paper
• Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease

  2021cites this paper
• Alternativas Terapêuticas ao uso da Hidroclorotiazida em Pacientes Diabéticos e Hipertensos / Therapeutic Alternatives to the use of Hydrochlorothiazide in Diabetic and Hypertensive Pacients

  2021cites this paper
• Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

  2021cites this paper
• Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT)

  2021cites this paper
• A Genome-Wide Association Study Identifies a Novel Susceptibility Locus at The DLGAP1 Gene For Resistant Hypertension in The Japanese Population

  2021cites this paper
• Resistant or refractory hypertension: it is not just the of number of drugs.

  2021cites this paper
• Role of Blood Pressure Management in Stroke Prevention: A Systematic Review and Network Meta-Analysis of 93 Randomized Controlled Trials

  2021cites this paper
• The attention on gender in studies on the treatment of hypertension : was it enough ?

  2021cites this paper
• Rationale and Design of the Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR) Trial.

  2021cites this paper
• Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia

  2020cites this paper
• Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST)

  2020cites this paper
• Die chronische koronare Herzkrankheit/das chronische Koronarsyndrom – Was sagen die deutschen und die europäischen Leitlinien?

  2020cites this paper
• Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study.

  2020cites this paper
• ETIOLOGY OF HYPONATREMIA IN GERIATRIC AGE GROUP PRESENTING WITH ALTERED SENSORIUM IN WESTERN RAJASTHAN.

  2020cites this paper
• Felodipine in Treatment of Arterial Hypertension and Ischemic Heart Disease

  2020cites this paper
• Prevalence of Resistant Hypertension in Hypertension and Research Center, Rangpur

  2020cites this paper
• Cardiovascular outcome and home blood pressure in relation to silent myocardial ischemia in a clinical population: The J‐HOP study

  2020cites this paper
• A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study

  2020cites this paper
• Pharmacogenetic factors affecting β-blocker metabolism and response

  2020cites this paper
• Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST☆☆

  2020cites this paper
• Regional Clinical Guideline for the Management of Stable Angina

  2020cites this paper
• Hypertension and Diabetes: Risk, Interaction, and Management Target

  2020cites this paper
• Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials.

  2020cites this paper
• Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease

  2020cites this paper
• THE INDEPENDENT ASSOCIATION OF BPD WITH MYOCARDIAL LESIONS (USING HIGH SENSITIVITY DATA) TROPONIN-T CARDIAC AND IN THE EVENT OF CORONARY HEART DISEASE

  2020cites this paper
• Effect of Low Diastolic Blood Pressure to Cardiovascular Risk in Patients With Ischemic Stroke or Transient Ischemic Attacks Under Different Systolic Blood Pressure Levels

  2020cites this paper
• Hypertension in Metabolic Syndrome: novel insights.

  2020cites this paper